Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Asset Resilience Ratio
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has an Asset Resilience Ratio of 9.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥286.82 Million | 9.91% |
| Total Liquid Assets | CN¥286.82 Million | 9.91% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Wolwo Bio-Pharmaceutical Co Ltd maintains only 9.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705 |
Drug Manufacturers - General | 5.75% |
|
Hunan Jingfeng Pharmaceutical
SHE:000908 |
Drug Manufacturers - General | 0.38% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367 |
Drug Manufacturers - General | 32.14% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198 |
Drug Manufacturers - General | 0.00% |
|
PharmGen Science Inc
KO:004720 |
Drug Manufacturers - General | 0.16% |
Annual Asset Resilience Ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.24% | CN¥196.09 Million | CN¥2.71 Billion | +2.66pp |
| 2023-12-31 | 4.58% | CN¥117.39 Million | CN¥2.56 Billion | -8.84pp |
| 2022-12-31 | 13.42% | CN¥295.05 Million | CN¥2.20 Billion | -5.78pp |
| 2021-12-31 | 19.20% | CN¥370.93 Million | CN¥1.93 Billion | +0.07pp |
| 2020-12-31 | 19.13% | CN¥307.03 Million | CN¥1.60 Billion | +16.24pp |
| 2019-12-31 | 2.90% | CN¥41.37 Million | CN¥1.43 Billion | -8.07pp |
| 2018-12-31 | 10.97% | CN¥116.00 Million | CN¥1.06 Billion | -24.40pp |
| 2017-12-31 | 35.36% | CN¥300.00 Million | CN¥848.31 Million | +10.83pp |
| 2016-12-31 | 24.54% | CN¥171.00 Million | CN¥696.89 Million | +8.18pp |
| 2015-12-31 | 16.35% | CN¥100.00 Million | CN¥611.49 Million | +5.06pp |
| 2014-12-31 | 11.29% | CN¥60.00 Million | CN¥531.31 Million | -- |